Chardan KOL Call: Small Cell Lung Cancer and Commercial Outlook for Lurbinectedin Featuring KOL Dr. Wade Iams & PharmaMar (PHM.MC) Management Moderated by Keay Nakae, CFA, Senior Research Analyst.

Participating Management:

Pascal Besman, PharmaMar, Chief Operating Officer, US
Jose Luis Moreno, PharmaMar, Director, Capital Markets and IR
Wade Iams, MD, Vanderbilt Ingram Cancer Center, Assistant Professor of Medicine

For more information about Chardan’s conference call, please email CorpAccess@chardan.com.

Access Replay Here